This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A Review of Approaches for the Management of Specialty Pharmaceuticals in the United States
PharmacoEconomics Open Access 14 August 2014
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Adams, K.T. Biotechnol. Healthcare. 3, 28–35 (2006).
Mullins, C.D., Lavallee, D.C., Pradel, F.G., DeVries, A.R. & Caputo, N. Health Aff. (Millwood) 25, 1332–1339 (2006).
Robinson, J.C. Health Aff. (Millwood) 25, 1205–1217 (2006).
Tseng, C.W., Mangione, C.M., Brook, R.H., Keeler, E. & Dudley, R.A.J. Am. Med. Assoc. 297, 2596–2602 (2007).
Bowman, J., Rousseau, A., Silk, D. & Harrison, C. Health Aff. (Millwood) 25, 1240–1248 (2006).
Comer, B. IMS: Global biotech sales up 12.5% in 2007. (2008) http://www.mmm-online.com/IMS-Global-biotech-sales-up-125-in-2007/article/111366/.
Stern, D. & Reissman, D. J. Manag. Care Pharm. 12, 736–744 (2006).
Hargrave, E., Hoadley, J. & Thompson, J. Coverage and Pricing of Drugs That Can Be Covered Under Part B and Part D (MedPAC, Washington, DC, 2007).
Huskamp, H.A., Stevenson, D.G., Donohue, J.M., Newhouse, J.P. & Keating, N.L. Psychiatr. Serv. 58, 308–310 (2007).
Hargrave, E., Hoadley, J. & Merrell, K. Drugs on Specialty Tiers in Part D (MedPAC, Washington, DC, 2009).
Hoadley, J., Hargrave, E., Cubanski, J. & Neuman, T. Medicare Part D Data Spotlight: Specialty Tiers (Kaiser Family Foundation, Menlo Park, California, USA, 2009).
Walsh, B. The Tier 4 Phenomenon: Shifting the High Cost of Drugs to Consumers (AARP, Washington, DC, 2009)
Acknowledgements
The authors are grateful for contributions to this paper from C. Hosenfeld. This study was funded by two grants to K.A.P. from the US National Cancer Institute (R01CA101849 and P01CA130818) and a grant from the Aetna Foundation (unrestricted).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
S.-Y.L., J.S.H. and K.A.P. received funding from a research grant from the Aetna Foundation to study the utilization of emerging genomic technologies. J.S.H. received salary support from a research grant from Pfizer to study reporting of adverse drug events to the FDA.
Rights and permissions
About this article
Cite this article
Liang, SY., Haas, J. & Phillips, K. Medicare formulary coverage for top-selling biologics. Nat Biotechnol 27, 1082–1084 (2009). https://doi.org/10.1038/nbt1209-1082
Issue Date:
DOI: https://doi.org/10.1038/nbt1209-1082
This article is cited by
-
Insurance Coverage of Biologics for Moderate-to-Severe Psoriasis: A Retrospective, Observational 5-Year Chart Review
American Journal of Clinical Dermatology (2016)
-
A Review of Approaches for the Management of Specialty Pharmaceuticals in the United States
PharmacoEconomics (2014)